Rhea: Effect of an Exploratory Vehicle on Meibomian Gland Dysfunction in Patients With Demodex
Study Details
Study Description
Brief Summary
The purpose of this study is to evaluate and compare the effect of two dosing regimens, BID versus TID dosing, of an Exploratory Vehicle (EV) on meibomian gland dysfunction (MGD) in patients with Demodex lid infestation.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 2 |
Detailed Description
This is a prospective, randomized controlled, three-arm, investigator- and interpreter-masked study. This study is intended to compare the effect of two dosing regimens of an exploratory vehicle on meibomian gland dysfunction (MGD) in participants with Demodex lid infestation. Approximately 12 participants will be enrolled in each arm. The administration period will last for approximately 85 days.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Study Cohort 1 Participants who were previously enrolled, dosed, and completed approximately 43 days of TID EV administration. Participants are crossed over to receive BID administration of EV for approximately 43 additional days. |
Drug: Vehicle of TP-03
The Exploratory Vehicle is the vehicle of TP-03 (lotilaner ophthalmic solution, 0.25%)
Other Names:
|
| Experimental: Study Cohort 2 Participants are randomized to receive BID administration of EV for approximately 85 days. |
Drug: Vehicle of TP-03
The Exploratory Vehicle is the vehicle of TP-03 (lotilaner ophthalmic solution, 0.25%)
Other Names:
|
| Experimental: Study Cohort 3 Participants are randomized to receive TID administration of EV for approximately 85 days |
Drug: Vehicle of TP-03
The Exploratory Vehicle is the vehicle of TP-03 (lotilaner ophthalmic solution, 0.25%)
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Treatment Emergent Adverse Events (TEAEs) [85 days]
TEAEs related (definitely or potentially) to treatment summarized by MedDRA preferred term. TEAEs related (definitely or potentially) to treatment summarized by MedDRA preferred term.
Secondary Outcome Measures
- Change from baseline in lower lid meibomian gland secretion score [85 days]
For each of the 15 glands expressed, secretion characteristics will be graded via slit lamp examination on a scale of 0 to 3 (3=clear liquid secretion; 2=cloudy liquid secretion; 1=granularly opaque liquid secretion to inspissated/toothpaste consistency; and 0=no secretion).
- Change from baseline in lid margin erythema. [85 days]
Erythema of the eyelid margin will be assessed via slit lamp examination and graded on a scale of 0 (normal) to 3 (severe) for the upper and lower eyelids of each eye.
- Change from baseline in tear breakup time assessed via slit lamp [85 days]
Tear breakup time will be assessed via slit lamp examination and timed in seconds to two significant digits.
Eligibility Criteria
Criteria
Key Inclusion Criteria:
-
Be willing to sign the informed consent and deemed capable of complying with the requirements of the study protocol
-
Meets all of the following criteria in at least one eye: have more than 10 lashes with collarettes present on the upper lid; have the presence of one or more mites with lash epilation of the upper and lower lids; have evidence of meibomian gland dysfunction; have at least mild erythema of the lower lid; have a tear breakup time of less than 10 seconds; and have intact partial to full meibomian glands in at least 33% of the total meibomian gland area of the lower lid
Key Exclusion Criteria:
-
Have used lid hygiene products within 7 days of Day 1 or unwilling to forego the use of lid hygiene products during the study
-
Have used systemic antihistamines within 30 days of Day 1
-
Have used artificial eyelashes, eyelash extensions, or had other cosmetic eyelash or eyelid procedures within 7 days of Day 1 or be unwilling to forego their use during the study
-
Contact lens wear within 7 days of Day 1 or unwilling to forego contact lens wear for the duration of the study
-
Be pregnant or lactating at Day 1
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Shultz Chang Vision | Northridge | California | United States | 91325 |
| 2 | Vita Eye Clinic | Shelby | North Carolina | United States | 28150 |
Sponsors and Collaborators
- Tarsus Pharmaceuticals, Inc.
Investigators
- Principal Investigator: Mitchell C Shultz, MD, Shultz Chang Vision
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- TRS-021